Lumiio recently announced in partnership with MitoCanada, the launch of a new patient registry for mitochondrial diseases. The registry will allow for centralized data collection from patients and their families. Providing this data to health communities and their stakeholders will allow for expedited drug discovery, faster diagnoses and ultimately deeper insights to help improve quality of life for patients.
There are over 300 known diseases associated with mitochondrial dysfunction, with an estimated 1 in 4,000 people worldwide are affected. None of these diseases presently have a cure, so having a registry that can inform treatment development is fulfilling a necessary gap for patients and their families all over the world.
